Report : Middle East & Africa Malaria Treatment Market Forecast to 2030 - Regional Analysis - by Treatment (Generic Drugs, Originators, Vaccines, and Others), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
At 28.5% CAGR, Middle East & Africa Malaria Treatment Market is Speculated to be Worth US$ 15,512.97 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the Middle East & Africa malaria treatment market was valued at US$ 2,091.28 million in 2022 and is expected to reach US$ 15,512.97 million by 2030, registering a CAGR of 28.5% from 2022 to 2030. Increasing prevalence of malaria and rising initiatives to raise awareness about malaria are among the critical factors attributed to the Middle East & Africa malaria treatment market expansion.
Malaria, one of the acute febrile illnesses, is caused by plasmodium parasites and spreads through the infected female Anopheles mosquitoes. Five parasite species in humans mainly cause malaria, and two of these species-Plasmodium falciparum and P. vivax-are considered the greatest threat to human health. Also, P. falciparum is the deadliest malarial parasite, and it is most widely spread across the African continent. Further, P. vivax is the dominant malarial parasite in most countries outside of sub-Saharan Africa. According to the latest World Malaria Report (WMR) 2020 from the World Health Organization (WHO), 241 million cases of malaria were reported in the world, in comparison to 227 million cases that were logged in 2019. According to the same source, the number of deaths caused due to malaria has an annual rise of 69,000 deaths. Approximately two-thirds of these deaths, i.e., 47,000, were caused by disruptions in healthcare services during the COVID-19 outbreak; the remaining one-third of deaths, i.e., 22,000 reflected a recent change in the WHO's methodology for calculating malaria mortality (irrespective of COVID-19 disruptions).
The WHO African region accounted for a high share of the global burden of malaria. In 2020, ~95% of global cases and ~96% of deaths were reported in Africa due to malaria, and ~80% of the total deaths that were reported were in children aged 5 and below. According to the WHO, four African countries, Nigeria, Tanzania, the Democratic Republic of the Congo, and Mozambique, recorded approximately half of all malaria-related deaths that were reported globally. According to the LANCET Regional Health 2020, African countries had the highest burden of malaria; P. falciparum is a notable cause of the highest mortality rates in children younger than 5, which accounts for ∼77% across the world; in African countries, P. falciparum accounts for ∼96% of total mortalities caused among children by malaria. P. vivax has been a causal agent of 2% (4.5 million) of the total cases of malaria, mainly from Asia. Thus, the rising prevalence of malaria boosts the malaria treatment market growth.
On the contrary, availability of counterfeit antimalarial drugs followed by subsequent drug resistance hurdles the growth of Middle East & Africa malaria treatment market.
Based on treatment, the Middle East & Africa malaria treatment market is categorized into generic drugs, originators, vaccines, and others. The vaccines segment held 66.9% share of Middle East & Africa malaria treatment market in 2022, amassing US$ 1,399.84 million. It is projected to garner US$ 10,537.93 million by 2030 to expand at 28.7% CAGR during 2022-2030.
In terms of route of administration, the Middle East & Africa malaria treatment market is bifurcated into oral and parenteral. The oral segment held 76.6% share of Middle East & Africa malaria treatment market in 2022, amassing US$ 1,601.48 million. It is projected to garner US$ 11,695.33 million by 2030 to expand at 28.2% CAGR during 2022-2030.
By distribution channel, the Middle East & Africa malaria treatment market is categorized into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held 54.6% share of Middle East & Africa malaria treatment market in 2022, amassing US$ 1,129.18 million. It is projected to garner US$ 8,535.98 million by 2030 to expand at 28.8% CAGR during 2022-2030.
Based on country, the Middle East & Africa malaria treatment market has been categorized into South Africa, Saudi Arabia, the UAE, Kenya, Tanzania, Rwanda, Nigeria, Ghana, Uganda, Angola, Cameroon, Senegal, Zambia, and the Rest of Middle East & Africa. Our regional analysis states that the Rest of Middle East & Africa captured 47.2% share of Middle East & Africa malaria treatment market in 2022. It was assessed at US$ 986.25 million in 2022 and is likely to hit US$ 7,229.05 million by 2030, exhibiting a CAGR of 28.3% during 2022-2030.
Key players operating in the Middle East & Africa malaria treatment market are Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, and Lupin Ltd, among others.
- In January 2021, GSK and Novartis announce collaboration to support scientific research into genetic diversity in Africa.
- In October 2022, Pfizer completes acquisition of global blood therapeutics.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com